X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BBP-398 is a potential best-in-class SHP2 inhibitor being developed in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
Lead Product(s): BBP-398,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an EGFR inhibitor, in Phase 1 clinical study for the treatment of patients with non-small cell lung cancer with EGFR mutations.
Lead Product(s): BBP-398,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023
Details:
BBP-398 is an investigational SHP2 inhibitor, that links growth factor, cytokine and integrin signaling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. It is being investigated with opvido for advanced solid tumors.
Lead Product(s): BBP-398,Nivolumab
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
BBP-398 is a SHP2 inhibitor and as a monotherapy or in combination with other targeted therapies, could potentially be a promising therapy for patients with the KRAS G12C mutation.
Lead Product(s): BBP-398,Sotorasib
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Based on the terms of the agreement, BridgeBio will continue to lead its BBP-398, ongoing Phase 1 monotherapy and combination therapy trials. Bristol Myers Squibb will lead and fund all other development and commercial activities.
Lead Product(s): BBP-398
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $905.0 million Upfront Cash: $90.0 million
Deal Type: Licensing Agreement May 12, 2022
Details:
BBP-398 was developed through a collaboration with The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division. First clinical combination study set to evaluate safety and preliminary efficacy in non-small cell lung cancer with KRAS mutations.
Lead Product(s): BBP-398,Nivolumab
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: BridgeBio Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2021
Details:
The two-part Phase 1 study will examine the safety and preliminary anti-tumor activity. Part 1 will establish the recommended Phase 2 dose of BBP-398. Part 2 will examine preliminary anti-tumor activity in four cohorts of patients with certain molecular alterations.
Lead Product(s): BBP-398
Therapeutic Area: Oncology Product Name: IACS-15509
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Navire Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
